MediciNova completes double-blind phase of ALS trial for MN-166
Tweet Send to a Friend
MediciNova, Inc. (NASDAQ: MNOV) announced the completion of the last patient, last visit in the double-blind portion of COMBAT-ALS, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


